See more

Research

Introduction

The main purpose of LUSARA is research. Work at the lab is focused on the issue of bacterial resistance to antibiotics.

At LUSARA we believe that research must be primarily guided by curiosity, and not by marketing, impact or competitivity criteria.

We are not related in any way with governmental institutions, federal nor local, and we do not get public financing for research.

Laboratory

The research laboratory is equiped to perform microbiology and molecular biology projects. It has centrifugues, incubators, balances, electrophoresis equipment (including pulsed fields and acrylamide sequencing), electroporation, PCR, nucleic acid detection by hybridization, laminar flow hood, ultrafreezers (-70C and LN2) and a dark room.

Papers

On the prevalence of antibiotic resistance and factors that affect it:

NCBI COPY

Amábile Cuevas CF et al. (2001) Clin Infect Dis 32(suppl1):S30-2

NCBI COPY

Díaz-Mejía JJ et al. (2002) FEMS Microbiol Lett 217:173-6

NCBI COPY

López H et al. (2002) Rev Esp Quimioter 15:325-34

NCBI COPY

Delissalde F et al (2004) Int J Antimicrob Agents 24:405-8

NCBI COPY

Rosas I et al (2006) Int J Hyg Environ Health 209:461-70

NCBI COPY

Díaz-Mejía et al (2008) Microbiology 154:94-102

NCBI COPY

Arredondo-García JL et al. (2008) J Infect Devel Ctries 2:350-3

NCBI COPY

Arredondo-García JL et al. (2009) J Infect Devel Ctries 3:398-401

  COPY

Amábile-Cuevas CF et al. (2009) Rev Panam Infectol 11:31-6

NCBI COPY

Amábile-Cuevas CF et al (2010) J Appl Microbiol 108:158-62

NCBI COPY

Arredondo-García JL et al (2011) J Infect Devel Ctries 5:119-22

NCBI COPY

Amábile-Cuevas CF et al (2013) J Infect Chemother 19:1135-1140

NCBI COPY

Cristóbal-Azkarate J et al (2014) PLoS One 9:e107719

NCBI COPY

Kurenbach B et al (2015) mBio 6:e00009-15

NCBI COPY

Rosas I et al (2015) Curr Microbiol 71:490-495

On clinical trials and the use of antibiotics:

NCBI COPY

Arredondo-García JL et al. (2004) J Antimicrob Chemother 54:840-3

NCBI COPY

Urueta-Robledo J et al. (2006) Resp Med 100:1504-11

NCBI COPY

Arrieta JR et al. (2007) Am J Otolaryngol 28:78-82

NCBI COPY

Vick-Fragoso R et al. (2009) Infection 37:407-17

NCBI COPY

Amábile-Cuevas CF et al. (2011) J Antimicrob Chemother 66:1652-3

NCBI COPY

Levy-Hara G et al. (2011) Front Microbiol 2:230

  COPY

Amábile-Cuevas CF (2012) Chemother J 21:39-40

On the effect of ascorbate upon plasmids:

NCBI COPY

Amábile Cuevas CF (1988) Mutat Res 207:107-9

NCBI COPY

Amábile-Cuevas CF et al. (1991) Mutat Res 264:119-25

On the response of E. coli to superoxide stress:

NCBI COPY

Fuentes AM et al. (1997) FEMS Microbiol Lett 154:385-8

NCBI COPY

Fuentes AM et al. (1998) Microbiology 144:1731-6

NCBI COPY

Jiménez-Arribas G et al. (2001) FEMS Microbiol Lett195: 175-7

NCBI COPY

Fuentes AM et al. (2001) FEMS Microbiol Lett 201:271-5

On antimicrobial activity of novel pyridines:

COPY

Toscano RA et al. (1997) Chem Pharm Bull 45:957-61

COPY

Toscano RA et al. (2000) Heteroatom Chem 11:308-12

Methods:

COPY

Amábile-Cuevas CF (2013) J Global Antimicrob Resist 1:17-21

 

Education


Introduction

“Ivory tower” research benefits only the researcher. Despite not having any kind of public financing, at LUSARA we believe that education is the main product of research.

Therefore, we devote a sustantial effort to education, including courses, conferences and the formation of new researchers.

We also have an extensive record of books and reviews, serving specialized readers with integrating views and approaches; and articles in general-readership magazines, reaching the lay public.

Theses

Our laboratory housed several undergraduate and graduate theses projects, from the Universidad Iberoamericana, and the School of Biological Sciences and the School of Medicine and Homeopathy of the National Polythechnic Institute.

Although we are no longer receiving students, theses projects from other institutions have been supported in different ways.

Services

Introduction

Most financial resources that LUSARA devotes to research and education, come from services offered to pharmaceutical companies. We are especially able to communicate molecular, biochemical or pharmacological aspects of a product to the medical community, in a comprehensible and usable way. We have reached virtually all medical specialties with conferences, literature or multimedia materials. The laboratory has also been involved in clinical or in vitro trials involving antibiotics.

Research

At our microbiology/molecular biology laboratory, we have provided support for clinical trials, as well as performed in vitro research projects. Among the later, we developed an HCV-HBV viral-load assessing method (before one was approved by FDA). Also, we have carried out susceptibility surveillance projects for cefditoren, cefdinir, ceftibuten, ciprofloxacin, colistin, ertapenem, isepamicin, moxifloxacin, nitrofurantoin, tigecycline and voriconazole. Some of them have been published in international journals.

On the other hand, most of the phase-II and phase-III clinical trials done in Mexico, leading to the licensing of moxifloxacin, were supported by LUSARA’s lab services. We were also involved in clinical trials for ciprofloxacin (phase III), faropenem (fase II) and nitrofurantoin (post-marketing).